Clinical Trials Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 935-946
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.935
Genome-wide methylation profiling of early colorectal cancer using an Illumina Infinium Methylation EPIC BeadChip
Yu-Ling Wu, Tao Jiang, Wei Huang, Xing-Yu Wu, Peng-Jun Zhang, Ya-Ping Tian
Yu-Ling Wu, Wei Huang, Medical School of Chinese PLA, Beijing 100853, China
Tao Jiang, Ya-Ping Tian, Medical Innovation Research Division, Chinese PLA General Hospital, Beijing 100853, China
Xing-Yu Wu, Nankai University School of Medicine, Tianjin 300071, China
Peng-Jun Zhang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital and Institute, Beijing 100142, China
Author contributions: Wu YL, Jiang T, Zhang PJ and Tian YP designed the study; Wu YL performed the research, wrote the paper; Wu YL and Jiang T analyzed the data, and revised the manuscript for final submission; Huang W, Wu XY participated in the processing of bioinformatic analysis; Wu YL and Jiang T contributed equally to this study; Zhang PJ and Tian YP are the co-corresponding authors; and all authors have read and approve the final manuscript.
Supported by National Natural Science Foundation of China, No. 81972010; the National Key Research and Development Program of China, No. 2020YFC2002700, and No. 2020YFC2004604.
Institutional review board statement: The study was reviewed and approved by the Medical Ethics Committee of PLA General Hospital.
Clinical trial registration statement: We declared that this study has been reviewed and approved by the Medical Ethics Committee of PLA General Hospital. The number was S2022-003-01.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other individuals or organizations that can inappropriately influence our work and that there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in or the review of the manuscript.
Data sharing statement: No additional data are available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ya-Ping Tian, MD, Professor, Medical Innovation Research Division, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. tianyp@301hospital.com.cn
Received: December 19, 2021
Peer-review started: December 19, 2021
First decision: February 21, 2022
Revised: February 21, 2022
Accepted: April 3, 2022
Article in press: April 3, 2022
Published online: April 15, 2022
Processing time: 116 Days and 20.4 Hours
Core Tip

Core Tip: DNA methylation is associated with the growth and development of colorectal cancer (CRC). CRC usually develops from its precancerous lesion, colorectal adenoma. The study demonstrated that the Illumina Infinium Human Methylation 850K BeadChip can be used to investigate genome-wide methylation status of plasma DNA in early CRC and colorectal adenoma patients.